{"id":2507,"date":"2018-01-16T18:25:03","date_gmt":"2018-01-16T12:55:03","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2507"},"modified":"2021-07-24T12:56:54","modified_gmt":"2021-07-24T07:26:54","slug":"notizia-64","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-64","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>UK based company conducting clinical trials on World&#8217;s First Universal Flu Vaccine <\/strong><\/p>\n<p style=\"text-align: justify;\">UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world. Currently, there is no vaccine in the market that can be used for multiple flu problems. The company has got the patent for the vaccine MVA-NP+M1 and so far has been successfully tested for safety across 145 people.<\/p>\n<p style=\"text-align: justify;\"><strong>First ever treatment for breast cancer with a certain inherited genetic mutation approved by USFDA<\/strong><\/p>\n<p style=\"text-align: justify;\">USFDA has recently approved Lynparza (olaparib tablets) for the treatment of patients with certain types of breast cancer that have metastasized and tumors having a specific inherited genetic mutation. It is by far the only drug in its class (PARP inhibitor) approved for the treatment of breast cancer, and also the first one to treat certain patients with metastatic breast cancer having &#8220;BRCA&#8221; gene mutation.<\/p>\n<p style=\"text-align: justify;\"><strong>Immunology player KWS BioTest bought by Charles River for USD 20 million<\/strong><\/p>\n<p style=\"text-align: justify;\">Immunology player British CRO KWS BioTest is now a part of Charles River Laboratories after a deal worth USD 20 million, boosting the portfolio of Charles River in different therapeutic areas namely immuno-oncology and inflammatory and infectious diseases. KWS Biotest specializes in offering in vitro and in vivo testing services in immunology.<\/p>\n<p style=\"text-align: justify;\"><strong>Forty Seven added Roche as a second partner for developing CD47 cancer immunotherapy<\/strong><\/p>\n<p style=\"text-align: justify;\">Forty Seven has recently added Roche as a second partner for its CD47-targeted immuno-oncology drug candidate, Roche\u2019s Genentech unit has agreed to sponsor two trials of the antibody in combination with its PD-L1 inhibitor Tecentriq. This is a second partnership signed for the lead drug Hu5F9-G4 after getting Merck KGaA onboard last November to test the drug in combination with the recently approved Bavencio in a Phase 1b ovarian cancer trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>UK based company conducting clinical trials on World&#8217;s First Universal Flu Vaccine UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world. Currently, there is no vaccine in the market that can be used for multiple flu problems. The company [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1292,1299,1297,70,684,985,1294,1295,1296,17614,17613,11777,1300,1298],"industry":[17225],"therapeutic_areas":[17238,17227,17231],"class_list":["post-2507","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-retinaldegeneration","tag-age-related-macular-degeneration","tag-alkeus-pharmaceuticals","tag-allergan","tag-astellas","tag-glaxosmithkline","tag-novartis-brolucizumab","tag-ohr-pharmaceutical-ohr-102","tag-ophthotech-pegpleranib","tag-retinal-degeneration","tag-retinal-degeneration-market","tag-retinitis-pigmentosa","tag-retrolental-fibroplasia","tag-stargardt-disease","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-infectious-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>UK based company conducting clinical trials on Universal Flu Vaccine<\/title>\n<meta name=\"description\" content=\"UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-64\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UK based company conducting clinical trials on Universal Flu Vaccine\" \/>\n<meta property=\"og:description\" content=\"UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-64\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-16T12:55:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2450\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UK based company conducting clinical trials on Universal Flu Vaccine","description":"UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-64","og_locale":"en_US","og_type":"article","og_title":"UK based company conducting clinical trials on Universal Flu Vaccine","og_description":"UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world.","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-64","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-01-16T12:55:03+00:00","article_modified_time":"2021-07-24T07:26:54+00:00","og_image":[{"width":2450,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-64","url":"https:\/\/www.delveinsight.com\/blog\/notizia-64","name":"UK based company conducting clinical trials on Universal Flu Vaccine","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-64#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-64#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","datePublished":"2018-01-16T12:55:03+00:00","dateModified":"2021-07-24T07:26:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-64"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-64#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","width":2450,"height":1080,"caption":"News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">#RetinalDegeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alkeus Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Allergan<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Astellas<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GlaxoSmithKline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Novartis (Brolucizumab)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ohr Pharmaceutical (OHR-102)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ophthotech (Pegpleranib)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinal Degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinal Degeneration Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">retrolental fibroplasia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Stargardt Disease<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">#RetinalDegeneration<\/span>","<span class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/span>","<span class=\"advgb-post-tax-term\">Alkeus Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Allergan<\/span>","<span class=\"advgb-post-tax-term\">Astellas<\/span>","<span class=\"advgb-post-tax-term\">GlaxoSmithKline<\/span>","<span class=\"advgb-post-tax-term\">Novartis (Brolucizumab)<\/span>","<span class=\"advgb-post-tax-term\">Ohr Pharmaceutical (OHR-102)<\/span>","<span class=\"advgb-post-tax-term\">Ophthotech (Pegpleranib)<\/span>","<span class=\"advgb-post-tax-term\">Retinal Degeneration<\/span>","<span class=\"advgb-post-tax-term\">Retinal Degeneration Market<\/span>","<span class=\"advgb-post-tax-term\">Retinitis Pigmentosa<\/span>","<span class=\"advgb-post-tax-term\">retrolental fibroplasia<\/span>","<span class=\"advgb-post-tax-term\">Stargardt Disease<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Jan 16, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Jan 16, 2018 6:25 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2507","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2507"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2507\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2507"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2507"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2507"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2507"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2507"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}